Cohance Lifesciences Q1 PAT may dip 64.2% YoY to Rs 51.6 cr: ICICI Securities

ICICI Securities has come out with its first quarter (April - June’ 26) earnings estimates for the Pharma sector. The brokerage house expects Cohance Lifesciences to report net profit at Rs 51.6 crore down 64.2% year-on-year (down 29.6% quarter-on-quarter).

Net Sales are expected to decrease by 34.3 percent Y-o-Y (up 13.2 percent Q-o-Q) to Rs 552.4 crore, according to ICICI Securities.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 54.9 percent Y-o-Y (down 5.4 percent Q-o-Q) to Rs 118.8 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.